ReviewPsychedelic medicine (New Rochelle, N.Y.)2024
The Therapeutic Potential of Psychedelics on Reducing Rumination: A Mini-Review.
Review in Psychedelic medicine (New Rochelle, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rumination is a well-established risk factor for the onset and maintenance of depression and anxiety and is associated with various other forms of psychopathology (e.g., eating pathology, obsessive-compulsive disorder, posttraumatic stress disorder). Evidence suggests that rumination is a transdiagnostic process that may play a key role in the comorbidity of such disorders. However, rumination and related disorders are often difficult to treat and frequently resistant to change, often rendering conventional modes of treatment (e.g., psychotherapy and pharmacology) unsuccessful. A recent renaissance of psychedelic research shows promise in treating psychopathology with potential for acting on ruminative processes. Though theoretical explanations for the therapeutic effects of psychedelics implicate the reduction of rumination via changes in the default mode network, a limited number of studies have tested this link directly. This mini-review examined the existing empirical research linking psychedelic use and rumination. The results from six studies demonstrate a significant association between psychedelic use and lower levels of rumination, providing evidence that rumination may serve as a key cognitive factor in psychedelic treatment. Further research should explore whether identifying ruminative tendencies and encouraging the practice of disengaging from rumination before the psychedelic treatment session, particularly for those who report high levels of rumination, may result in better adherence to "letting go" during the session. Moreover, due to a possible diminishing effect of therapeutic outcomes after a single psychedelic dosing session, "booster" sessions may provide psychological relief once more; however, financial treatment costs are expectedly high. As such, understanding the role of rumination in psychedelic treatment can be critical for maintenance strategies (e.g., rumination-focused cognitive behavior therapy, mindfulness techniques) in postdosing integration sessions and long-term treatment plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.